Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients

Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease

“…This result may reflect the true lack of effect of the Mediterranean diet on the selected risk markers, or may be due to the meanwhile improved treatment options in CAD, which may have overshadowed any additional effect of the diet. Recent research has shown that statins have the capability to reduce vascular inflammation and effectively decrease hs-CRP concentrations in cardiovascular risk patients (Ascer et al, 2004, Koh et al, 2004. In contrast to most previous studies Mediterranean diet and inflammation A Michalsen et al on Mediterranean diet in CAD, in our study 80% of the patients were treated with statins, and the low baseline median hs-CRP concentrations did not indicate the presence of systemic inflammation.…”

Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?

“…In separate, randomized prospective studies of patients with hypercholesterolemia and hypertension, treatment with simvastatin resulted in decreased circulating IL-1␤, and IL-1␤ production by isolated PBMCs, respectively (82,83). Both atorvastatin and simvastatin significantly decrease levels of circulating IL-6 and TNF␣, in addition to IL-1␤, in patients with hypercholesterolemia (39,41,59,84). Carotid plaques resected from patients taking statins contain significantly lower concentrations of IL-6 (P ϭ 396 ABELES AND PILLINGER 0.0005), suggesting that statins do, indeed, alter local inflammation in atherosclerotic lesions (85).…”

“…Perhaps of greater significance is that a number of ex vivo human studies showed that statins downregulate the soluble concentration of these molecules. Shed (soluble) adhesion molecules are well-known markers for atherosclerotic disease (36)(37)(38), and several studies indicated that statins down-regulate circulating soluble ICAM-1, vascular cell adhesion molecule 1 (39)(40)(41), and E-and P-selectin (42,43). However, not all studies that examined the effects of statins on the soluble levels of these molecules have replicated these findings (44,45).…”

Estudo da atividade inflamatória e plaquetária em pacientes com doença arterial coronária estável, submetidos a tratamentos com duas estratégias hipolipemiantes intensivas: sinvastatina 80mg e ezetimiba 10mg/sinvastatina 20mg

“…Para mensurar a ação anti-inflamatória das estatinas, diversos marcadores foram investigados nas últimas décadas 32,41 . Entre eles, …”

“…Previamente, atorvastatina reduziu os níveis séricos de IL-1β após 8 semanas de tratamento em pacientes dislipidêmicos 41 .…”